Novel non-operative treatment and treatment strategies in pancreatic cancer (Q34074879)

30 July 2017

1 reference

title

Novel non-operative treatment and treatment strategies in pancreatic cancer (English)

1 reference

30 July 2017

1 reference

Bramhall SR

1

1 reference

PubMed ID

11060735

30 July 2017

language of work or name

English

0 references

publication date

1 June 2000

1 reference

Expert Opinion on Investigational Drugs

30 July 2017

1 reference

30 July 2017

9

1 reference

30 July 2017

6

1 reference

30 July 2017

1179-1195

1 reference

One hundred and forty-five consecutive pancreaticoduodenectomies without mortality

30 July 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1179

Cancer of the pancreas. 50 years of surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1179

Chemotherapy for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1179

A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1179

Clinical response to systemic combined chemotherapy with 5-fluorouracil and cisplatin (FP therapy) in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1179

Chemotherapy prolongs survival in inoperable pancreatic carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1179

Adjuvant chemotherapy after resection of adenocarcinoma of the periampullary region and the head of the pancreas. A non-randomized pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1179

Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1179

Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1179

Phase II study of gemcitabine in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1179

A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1179

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1179

Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1179

Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1179

Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1179

Weekly gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1179

Clinical and histopathological appraisal of preoperative irradiation for adenocarcinoma of the pancreatoduodenal region

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1179

Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1179

Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1179

Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1179

Over-expression of tissue inhibitor of matrix metalloproteinases (TIMP1 and TIMP2) suppresses extravasation of pulmonary metastasis of a rat bladder carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1179

Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library. MT-MMPs form a unique membrane-type subclass in the MMP family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1179

The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1179

Identification and preliminary characterization of protein-cysteine farnesyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1179

Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1179

Suppression of human pancreatic cancer growth in BALB/c nude mice by manumycin, a farnesyl:protein transferase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1179

Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1179

Therapeutic effect of the gastrin receptor antagonist, CR2093 on gastrointestinal tumour cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1179

Genetic mechanisms of tumor suppression by the human p53 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1179

Molecular advances in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1179

Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1179

Gene therapy for head and neck cancer. Comparing the tumor suppressor gene p53 and a cell cycle regulator WAF1/CIP1 (p21).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1179

Activation by thymidine kinase and potent antiherpetic activity of 2′-nor-2′-deoxyguanosine (2′NDG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1179

Gene therapy of metastatic pancreas cancer with intraperitoneal injections of concentrated retroviral herpes simplex thymidine kinase vector supernatant and ganciclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1179

Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1179

2,4-dinitro-5-ethyleneiminobenzamide (CB 1954): a potent and selective inhibitor of the growth of the Walker carcinoma 256.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1179

Gene-directed enzyme prodrug therapy: quantitative bystander cytotoxicity and DNA damage induced by CB1954 in cells expressing bacterial nitroreductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1179

Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1179

Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gln-->Leu61).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1179

Virtual cofactors for an Escherichia coli nitroreductase enzyme: Relevance to reductively activated prodrugs in antibody directed enzyme prodrug therapy (ADEPT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1179

10.1517/13543784.9.6.1179

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

11060735